To include your compound in the COVID-19 Resource Center, submit it here.

2Q Approvals

2Q Approvals

Company Approvals
AstraZeneca (LSE:AZN; AZN) FDA approves Iressa gefitinib as third-line monotherapy in advanced non-small cell

Read the full 180 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE